Versatope

Versatope Therapeutics delivers immunity with nanometer-size vesicles using a synthetic biology technology platform licensed from Cornell University. These nanovesicles are derived from the outer membrane of a genetically engineered and detoxified E. coli probiotic bacterial strain. This technology enables recombinant proteins to be expressed and delivered within a time-release vesicle that has the potential to be spray-dried or lyophilized for increased stability. When we used this proprietary technology to protect against influenza, we achieved complete protection against different strains of influenza with a single immunization due to the induction of potent cellular and antibody immune responses. Based on our findings, this technology may eliminate the need for yearly immunizations by serving as a universal flu vaccine. This platform technology is applicable to multiple infectious diseases (human and veterinary applications), allergy treatments, and cancer immuno-therapies. Key papers and patents have been published and additional manuscripts are in preparation. Versatope Therapeutics was founded in 2017 and is headquartered in Lexington, Massachusetts. Twitter: @VersatopeRx